Best practices as recommended by WHO and United States Pharmacopoeia are being implemented for performing tests on therapeutic goods.
Recent Updates
- 📌Notice for Documents Submission – Recruitment to the ten (10) posts of Deputy Director (Technical Cadre) (RO-13) – advertisement no. 01/2025July 24, 2025
- Minutes of the 348th Meeting of the Registration Board Held on 1st-2nd July, 2025July 24, 2025
- List of Establishment License under MDR 2017 (Local)July 23, 2025
- List of Establishment License under MDR 2017 (Import)July 23, 2025
- Requirement of Bio-equivalence Studies as part of Registration ApplicationJuly 23, 2025
- Inauguration of online system for the applications of Medical DevicesJuly 22, 2025
- Disposal of Applications of Biological ProductsJuly 22, 2025
- Health emergencies preparedness and risk management planJuly 21, 2025
- Guidance document for requirement of clinical trials or bio-similarity studies for registration of locally manufactured biological drugs for humansJuly 21, 2025
- Show all updates
Chief Executive Officer
- Dr. Obaidullah

E-Services
With the effective use of Information Technology, we have implemented a number of online services and continually working for more. Click here to browse available services.

Guidelines
Regulatory compliance is essential and indispensable in order to assure the safety, quality and efficacy of therapeutic goods. Guidance documents published by the Authority are meant to explain the current interpretation or policy for better understanding of the industry and

Quality Control Labs
For ensuring quality therapeutic goods, a network of quality control laboratories has been established. DRAP approved products and suspect therapeutic goods are tested for their quality in accordance with best international practices. To keep the citizens safe from substandard and

Therapeutic Products Recalls
The Recalled Product Index provides access to consumers, healthcare professionals, industry, hospitals and sale outlets related to the information of recalled action taken for defective therapeutic goods. The following section provides an index of recalled actions in which a public

Health Professional Alerts
DRAP’s issues safety updates and alerts related to the therapeutic goods in order to ensure that healthcare professionals and other stakeholders have timely access to the relevant information on safety, quality and efficacy issues or benefit/risk evaluations of the drugs,

Medicine Availability
The Drug Regulatory Authority of Pakistan (DRAP) is committed to safeguard public health by ensuring the consistent availability of safe, efficacious, and quality medicines nationwide. Recognizing the critical impact of drug shortages, particularly of essential and lifesaving medicines, on patient
New system for the applications of Medical Devices
We are thrilled to announce that the new MDMC Licensing and Registration module is officially launched. This enhanced module has been designed to offer a more streamlined, efficient, and user-friendly experience for managing all MDMC licensing and registration activities.
Do you know?
DRAP ensures that every drug, medical device or cosmetic, alternative medicine and health product must have a certain standard of quality and is safe and effective for your use. See in links below how it is done and what to do in case you find a suspect therapeutic good.